Quanterix’s fifth-generation digital immunoassay prostate specific antigen (PSA) test, demonstrated a 2-log improvement in sensitivity to measure PSA levels in patients following a radical prostatectomy.

The new PSA test based on proprietary single molecule array technology, forms a reliable predictor of five-year biochemical recurrence-free survival in men who have undergone radical prostatectomy for prostate cancer.

Quanterix Product Development senior director David Wilson said that the PSA assay could improve patient prognosis and inform clinical decisions for use of secondary therapy in individuals who have been treated surgically.